肿瘤热休克蛋白-抗原肽复合物疫苗的临床研究

热休克蛋白．抗原肽复合物（HSPPC）被称为个体化肿瘤疫苗。临床研究显示HSPPC用于肿瘤患者免疫接种是安全可行的,它能触发部分患者强有力的抗肿瘤免疫排斥反应,并产生一定临床效果。研究发现临床效果与免疫学反应间有一定相关性,且不良反应轻微,未观察到自身免疫现象。     

经腹膜外盆腔淋巴间隙给药对妇科肿瘤患者外周血T细胞亚群及NK细胞的影响

目的:探讨通过盆腔腹膜外淋巴间隙进行肿瘤生物治疗的可行性。方法:妇科恶性肿瘤患者31例随机分白细胞介素2(IL2)组(n=10)、IL2加氟尿嘧啶组(n=11)及氟尿嘧啶组(n=10)。通过经盆腔腹膜外淋巴间隙留置管,分别注射药物IL2、IL2加氟尿嘧啶、氟尿嘧啶,并在注药前后采集患者外周血,用流式细胞仪检测T细胞表面标记、CD25活化标记变化及NK细胞数量,用MTT比色法检测NK细胞杀伤活性。结果:各组治疗后外周血CD3+、CD4+、CD8+,CD25+、NK细胞数量及杀伤活性均比治疗前明显增高(P<0.05)。结论:经盆腔腹膜外淋巴间隙进行生物治疗能有效激活机体全身T细胞反应,促进T细胞增殖和活化,并促进NK细胞增殖和活化。     

应用RNA干扰技术阻断SYT-SSX表达治疗滑膜肉瘤的体外实验研究

目的研究siRNA(smallinterferingRNA)对滑膜肉瘤细胞系HS-SY-II中融合基因SYT-SSX表达的抑制作用,为RNAi技术在肿瘤生物治疗中的应用提供实验基础。方法体外合成3条针对滑膜肉瘤特异性融合基因SYT-SSX的siRNA,转染HS-SY-II细胞系,分别应用逆转录聚合酶链反应(RT-PCR)和Western杂交方法检测SYT-SSX基因和蛋白的表达情况,并用MTT比色法测定细胞的增殖活性,Annexin-FITC/PI双标记流式细胞计数检测细胞凋亡。结果设计的siRNA中,1条可以完全封闭SYT-SSX的转录,另2条分别使SYT-SSX基因表达降低至37.3%和70.1%。转染3条siRNA后,HS-SY-II细胞融合蛋白表达分别降低至75.03%、82.15%和16.59%。同时,细胞生长受到抑制,并发生细胞凋亡,凋亡率分别为32.51%、26.81%和47.19%。结论siRNA可以有效抑制HS-SY-II细胞系中融合基因SYT-SSX的表达,从而抑制细胞生长,并导致细胞凋亡。     

肿瘤热休克蛋白-抗原肽复合物疫苗的临床研究

热休克蛋白-抗原肽复合物(HSPPC)被称为个体化肿瘤疫苗。临床研究显示HSPPC用于肿瘤患者免疫接种是安全可行的,它能触发部分患者强有力的抗肿瘤免疫排斥反应,并产生一定临床效果。研究发现临床效果与免疫学反应间有一定相关性,且不良反应轻微,未观察到自身免疫现象。     

腹腔内化疗和温热化疗治疗中晚期消化道恶性肿瘤

目的 探讨治疗中晚期消化器官肿瘤术后复发或转移的安全、可靠和有效疗法。方法 回顾分析83例患者的临床资料。57例病人术后行腹腔化疗(IPC)和腹腔热化疗(IHC)。结果 IPC及IHC的总有效率为73％。其1、3、5、>5年的生存率分别为98.8％、33.7％、17.9％和12.3％。并用生物制剂组疗效较佳。无肝硬化者腹水控制率100％。结论 IPC及IHC是提高中晚期消化器官恶性肿瘤疗效,防治术后复发、转移和恶性腹水的有效手段。     

30例乳腺癌患者级联激活的免疫细胞治疗后细胞免疫功能变化

目的观察乳腺癌患者CAPRI细胞治疗前后T淋巴细胞亚群的变化及其临床意义.方法采用流式细胞术（FCM）检测30例乳腺癌患者化疗6周期后接受CAPRI细胞治疗1周期前后的淋巴细胞亚群并进行对比研究.结果接受CAPRI细胞治疗1周期后乳腺癌患者的外周血中的CD3＋细胞、CD4＋细胞、NK细胞的数量与接受CAPRI细胞治疗前相比均有较明显的提高（P〈0.05）,而CD8＋细胞的数量与接受CAPRI细胞治疗前相比没有较明显的改变（P〉0.05）.结论乳腺癌患者化疗结束后应用CAPRI细胞治疗对乳腺癌患者的细胞免疫功能具有明显改善作用.     

Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma

AIM: To analyze the correlation of treatment method with the outcome of all the hepatic metastatic mela-noma (HMM) patients from our hospital.METHODS: There were altogether nine cases of HMM that had been treated in the PUMCH hospital during the past 25 years, from December 1984 to February 2010. All of the cases developed hepatic metastasis from primary cutaneous melanoma. A retrospective review was performed on all the cases in order to draw informative conclusion on diagnosis and treatment in correlation with the prognosis. Clinical features including symptoms, signs, blood test results, Bultrasound and computed tomography (CT) imaging characteristics, and pathological data were analyzed in each case individually. A simple comparison was made on case by case basis instead of performing statistical analysis since the case numbers are low and patients were much diversified in each item that has been analyzed. Literatures on this subject were reviewed in order to draw a safe conclusion and found to be supportive to our finding in a much broad scope. RESULTS: There are six males and three females whose ages ranged 39-74 years old with an average of 58.8. Patients were either with or without symptoms at the time of diagnosis. The liver function and tumor marker exam were normal in all but one patient. The incidence of HMM does not affect liver function and was not related to virus infection status in the liver. Most of these HMM patients were also accompanied by the metastases of other locations, including lung, abdominal cavity, and cervical lymph nodes. Ultra-sound examinations showed lesions ranging 2-12 cm in diameter, with noor low-echo peripheral areola. Doppler showed blood flow appeared inside some tumors as well as in the surrounding area. CT image demonstrated low density without uniformed lesions, characterized with calcification in periphery, and en-hanced in the arterial phase. Contrast phase showed heterogeneous enhancement, with a density higher than normal liver tissue, which was especially appar-ent at the edge. Patients were treated differently with following procedures: patients #1, #6 and #8 were operated with hepatectomy with or without removal of primary lesion, and followed by comprehensive biotherapy/chemotherapy; patient #9 received hepatectomy only; patient #2 received bacille calmette-guerin treatment only; patient #7 had Mile’s surgery but no hepatectomy; and patients #3, #4 and #5 had supportive treatment without specific measurement. The patients who had resections of metastatic lesions followed by post-operative comprehensive therapy have an average survival time of 30.7 mo, which is much longer than those did not receive surgery treatment (4.6 mo). Even for the patient receiving a resection of HMM only, the post-operative survival time was 18 mo at the time we reviewed the data. This patient and the patient #6 are still alive currently and subjected to continue following up. CONCLUSION: Surgical operation should be first choice for HMM treatment, and together with biothera-py/chemotherapy, hepatectomy is likely to bring better prognosis.